Featured Research

from universities, journals, and other organizations

Epilepsy Drugs Useful To Treat Alzheimer's, Studies Find

Date:
July 22, 1998
Source:
University Of Rochester
Summary:
Medicines commonly used to treat epilepsy and other seizure disorders appear to be effective at soothing the agitation in people with Alzheimer's disease and other forms of dementia. The findings are a glimmer of good news for the treatment of some of the most disturbing aspects of the disease, which afflicts about 4 million people in the United States alone.

Medicines commonly used to treat epilepsy and other seizure disorders appear to be effective at soothing the agitation in people with Alzheimer's disease and other forms of dementia. The findings are a glimmer of good news for the treatment of some of the most disturbing aspects of the disease, which afflicts about 4 million people in the United States alone.

The results by University of Rochester scientists are being featured at a media briefing this week at the 6th International Conference on Alzheimer's Disease and Related Disorders in Amsterdam, the Netherlands.

Psychiatrists Pierre Tariot and Anton Porsteinsson, physicians at the University's main Alzheimer's treatment site at nearby Monroe Community Hospital, presented the results from several placebo-controlled studies showing that the compounds are effective in treating agitation among patients with dementia. The medicines appear to be as good as or better than the medicines physicians have available now to treat agitation, says Tariot. Patients' aggression and agitation are often the top concerns among families of patients, say physicians.

"The behavioral disturbances wear care givers down and are one of the main reasons that patients are admitted to acute and long-term care institutions," says Porsteinsson. "People don't put their husbands or mothers in nursing homes because they are forgetful; they're put in a nursing home because they are a danger to themselves or others, or because they're unbearably hostile or aggressive. This type of medicine alleviates those symptoms for many patients in a population that is a bear to treat."

About three-quarters of patients on the medicine carbamazepine improved in two of the studies, which were funded by the National Institutes of Health. The second study, with 51 patients, was halted prematurely because the drug appeared so effective that physicians concluded that further enrollment was not necessary and that all patients should have access to it.

Agitation is one of many symptoms that patients with Alzheimer's and other dementias develop as their brain cells get sick and die. The patients' memory and comprehension deteriorate, they become confused and disoriented, and ordinary tasks become impossible. Nine out of 10 patients have significant behavioral problems at some point, says Tariot, professor of psychiatry and neurology and director of the University's Program in Neurobehavioral Therapeutics at Monroe Community Hospital. There is no single best treatment for agitation, he says. Doctors have used sedatives and anti-psychotic drugs like haloperidol and thioridazine in the past, with only limited success.

Some doctors have previously reported case studies where anti-seizure medicines like carbamazepine seemed to improve Alzheimer's patients' symptoms. Doctors normally use the medicines to treat epilepsy and help patients control impulses or aggression similar to that seen in most Alzheimer's patients; use of the medications to treat dementia is growing as clinicians see the benefit.

"This is a case where medical science is trying to catch up with clinical practice," says Porsteinsson, an assistant professor of psychiatry. "The medicines are already being used, but there haven't been studies in place to determine just how safe and effective these agents are. That's what our work is all about." The team's studies are the first placebo-controlled trials of anti-seizure medications in the treatment of Alzheimer's disease.

Nurses measured behaviors like tension, hostility, and aggression -- screaming and yelling, hitting or spitting at care givers, verbally abusing them, throwing things, pacing, and other inappropriate actions. The nurses, who didn't know which patients were on placebo and which were receiving the medicine, watched and spoke with the patients and their care givers in nursing homes around Rochester. Doctors analyzing the results found that patients on the medicine were less aggressive and agitated, and nursing aides said those patients were more engaged in social activities and required less time to manage.

The team also presented preliminary results from a small, placebo-controlled pilot study of divalproex sodium, another common anti-seizure medication. The results of the study, sponsored by the Alzheimer's Association, are promising enough to spur a large multi-center trial, says Tariot. He is principal investigator of one such study that is just beginning; that study is being funded by Abbott Laboratories, which markets divalproex sodium under the brand name Depakote. A similar large study is being considered by the National Institute on Aging.

The Rochester team has pioneered the use of anti-seizure medications like carbamazepine and divalproex to treat Alzheimer's and also has expertise in studying and treating nursing home residents. "A nursing home is like a laboratory in which to study dementia in its worst form," says Tariot, who estimates that about three-quarters of nursing home residents have dementia, most from Alzheimer's disease.

Tariot's research group of about 20 doctors, nurses, and other staff is currently conducting about 20 studies with approximately 225 patients. The carbamazepine and divalproex studies included patients from Monroe Community Hospital, St. John's Home, the Jewish Home, St. Ann's Home, the Highlands Living Center, and the Veterans Administration Medical Center in Canandaigua. At the outpatient clinic at Monroe Community Hospital, the team treats an additional 400 patients on an ongoing basis.

"The field is evolving very rapidly," says Tariot, who is leading a symposium on treatment of behavioral disorders and dementia at the Amsterdam meeting. "Six years ago, there was nothing to treat Alzheimer's disease. Now, we have two FDA- approved drugs and as many as a dozen more coming out within five years. We're even talking about prevention strategies. It's very exciting and gratifying."


Story Source:

The above story is based on materials provided by University Of Rochester. Note: Materials may be edited for content and length.


Cite This Page:

University Of Rochester. "Epilepsy Drugs Useful To Treat Alzheimer's, Studies Find." ScienceDaily. ScienceDaily, 22 July 1998. <www.sciencedaily.com/releases/1998/07/980722080606.htm>.
University Of Rochester. (1998, July 22). Epilepsy Drugs Useful To Treat Alzheimer's, Studies Find. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/1998/07/980722080606.htm
University Of Rochester. "Epilepsy Drugs Useful To Treat Alzheimer's, Studies Find." ScienceDaily. www.sciencedaily.com/releases/1998/07/980722080606.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins